Ipamorelin lab tests

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂: CAS 170851-70-4 (PubChem CID 9831659), formula C₃₈H₄₉N₉O₅, molecular weight 711.9 g/mol, monoisotopic mass 711.3857 ([M+H]⁺ 712.3929), developer code NNC 26-0161. It carries no Trp-Trp core — the motif shared by GHRP-2, GHRP-6 and hexarelin — using Aib and D-2-naphthylalanine instead, so it is a genuinely different molecule rather than a one-residue variant, and it sits 106 to 175 daltons below every compound it is sold beside. Any mass spectrometer, including a low-resolution one, separates them, which makes an ipamorelin certificate with a purity figure and no identity result a choice rather than a technical limitation.

Because identity is nearly free to confirm, the realistic risks are underfill and non-peptide bulking: salts, residual water and bulking agents that a purity percentage will not reveal. FDA's compounding review called the free base "not well-characterized from the physical and chemical characterization perspective", with impurities, aggregates and endotoxin data missing. The Pharmacy Compounding Advisory Committee voted on the free base and the acetate as separate substances in October 2024, and it is ipamorelin acetate that sits on FDA's Category 2 list (added 29 September 2023), so a listing that names neither form has not specified the substance it is selling.

Confirming the molecule does not confirm the selectivity claim sold with it. Ipamorelin's lack of a cortisol and prolactin response was demonstrated in conscious swine by Raun et al. (1998), at doses more than 200-fold above its own GH ED₅₀; the familiar comparison with GHRP-2 and GHRP-6 mixes animal data for one compound with human data for the others.

One citation circulating on product pages is misattributed. A paper titled "Ipamorelin for postoperative ileus: results of phase II/III trials" is attributed to PMID 11600700, which is actually "The role of acetylation in rDNA transcription", a 2001 molecular biology paper in Nucleic Acids Research. No phase II/III ipamorelin publication exists, and a page citing one was not fact-checked.

• Mass spectrometry at 711.3857 monoisotopic, or 712.3929 as the [M+H]⁺ ion; a nominal-mass result is sufficient here.
• A mass at 817.4275 (GHRP-2), 872.4446 (GHRP-6) or 886.4602 (hexarelin) is a different secretagogue — gaps of 106.04, 161.06 and 175.07 Da.
• Net peptide content or amino acid analysis, reported separately from purity — the check that matches this compound's actual failure mode.
• An LAL endotoxin result on the batch; FDA named missing endotoxin data specifically.
• The form — free base or acetate — named on the label and the certificate.